Janice L. Gabrilove

Janice L. Gabrilove

Corporate Officer/Principal bij Icahn School of Medicine at Mount Sinai

Finance
Consumer Services

Profiel

Dr. Gabrilove, board certified in Internal Medicine and Medical Oncology, is the Vice Chairman of Clinical Research at the Department of Medicine at the Mount Sinai Medical Center, New York, NY.
She is a professor of Medical Oncology at Mount Sinai, Director of the Hematology/Oncology Fellowship Program, and Chairperson of the Clinical Care Committee.
She is the Inventor of the American, Canadian, and European patent use of the recombinant human granulocyte colony stimulating factor in the treatment of mucositis, the coinventor of the American and Canadian patent human pluripotent granulocyte colony stimulating factor and the coinventor of the American, Canadian, and European application stimulation of bone marrow stromal and progenitor cells by human basic fibroblast growth factor.
Dr. Gabrilove has served in an advisory capacity to a number of biotech companies and served for five years on the first FDA advisory board for the approval of biologics.
She is on the Executive committee of the American Society of Hematology, and received her medical degree from the Mount Sinai School of Medicine.

Actieve functies van Janice L. Gabrilove

BedrijvenFunctieBegin
Icahn School of Medicine at Mount Sinai Corporate Officer/Principal -
Alle actieve functies van Janice L. Gabrilove

Eerdere bekende functies van Janice L. Gabrilove

BedrijvenFunctieEinde
Corporate Officer/Principal -
Ervaring van Janice L. Gabrilove in detail bekijken

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Janice L. Gabrilove in detail bekijken

Connecties

47

Eerstegraads connecties

2

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit1

Finance

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Janice L. Gabrilove
-40 % Uitzonderlijk verlengd: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU